Home / Prepare Your Business for Sale / Dental Practice

How to Prepare Your Dental Practice for a Sale or Exit (2026)

Updated April 2026 · CT Acquisitions

Most dental owners accept the first unsolicited DSO offer that lands in their inbox and find out 9 months later that a real competitive process would have paid them 20% to 40% more. TUSK Practice Sales has been on the record warning practice owners that unsolicited DSO offers “leave significant value on the table” (TUSK Practice Sales / PR Newswire). The owners who get the top-quartile price start preparing 24 to 36 months before they ever talk to a buyer. This guide is the 36-month playbook for how to prepare your dental practice for a sale or exit. It covers what dental private equity and DSO platforms actually buy in 2026, the two valuation conventions that govern dental deals (percent of collections and EBITDA multiples), the 12 levers that move multiples, the documents PE will ask for before they send a letter of intent, and the deal-killers that re-trade dental transactions during confirmatory diligence. Every number cites its source. Every recommendation comes from how the most active DSO buyers in 2026 actually behave.

If you are 6 to 36 months from a possible exit, this is the work that turns a 6x EBITDA outcome into a 9x or 10x outcome. On a $1.5M EBITDA dental practice, that is the difference between a $9M sale and a $13.5M to $15M sale. Whether you want to prepare your dental practice for a sale to a DSO platform, prepare your dental practice for an exit to a regional roll-up or specialty consolidator, or simply maximize value over the next 1 to 3 years before going to market, the work below applies.

What Private Equity Actually Buys in Dental (2026)

Approximately 130 PE-backed DSOs are now operating across the dental services landscape, more than any other healthcare vertical (Private Equity Stakeholder Project, monthly healthcare PE reports, 2025). Dental was the busiest healthcare M&A category in 2024 with at least 161 PE-backed transactions, up 10.3% from 2023, and August 2025 alone produced at least 22 PE-backed dental deals (PESP, August 2025 monthly report). 16% of all US dentists are now DSO-affiliated, and among dentists less than 10 years out of dental school the figure jumps to 27% (ADA Health Policy Institute, 2024 Dentist Workforce Report). The sponsor money flowing into dental is not random. PE and DSO platforms buy specific profiles, and the profile you build determines the multiple you get.

The PE-attractive dental practice profile

• EBITDA threshold for a platform-quality deal: $1M to $3M is the entry band where DSO add-on programs run a competitive process for a single-location general practice. $3M to $5M EBITDA puts you in emerging-platform territory where ranges shift from add-on (5x to 8x) to platform-fit (9x to 11x). $5M+ EBITDA and you are a true platform candidate where multi-state OMS, multi-state ortho, and multi-specialty groups trade at 10x to 13x and above (FOCUS Investment Banking dental and specialty reports, 2025-2026).
• Recurring hygiene and recall: Hygiene production of 28% to 35% of total collections with recall reappointment above 85% is the line between commodity and premium. MyBCAT cites recall rate as “the single metric that most frequently separates $500K practices from $1M practices” (MyBCAT 2025). National average recall sits at 65% to 74%.
• Payer mix: Government payer (Medicaid + state programs) below 25% of collections; balanced PPO with negotiated above-UCR fee schedules where possible; meaningful FFS or cash or membership-plan share. Government payer above 35% suppresses the multiple by 10% to 30% and restricts the buyer pool (Precision Dental Analytics “11 Underwriting Criteria”).
• Owner-doc production share: Owner producing below 35% of collections is the target. Owner above 50% triggers a 1.0x to 2.0x EBITDA multiple haircut and frequently triggers a structure renegotiation with heavier earnout and multi-year post-close employment commitments (Precision Dental Analytics).
• Specialty mix: Single-specialty practices (orthodontics, oral surgery, endodontics, periodontics, pediatric dentistry) and multi-specialty groups command 2x to 4x higher EBITDA multiples than general-only practices (CT Acquisitions 2026; FOCUS Investment Banking specialty reports).
• Geography: Sun Belt, Texas, Florida, Carolinas, and Mountain West metros are where 2026 DSO demand concentrates. Rural single-location practices discount.
• Membership plan: 10%+ of the active patient base on an in-house monthly plan ($35 to $49/month is the pricing sweet spot per DentalHQ 2025). Membership patients generate $1,276 annually vs. $469 from uninsured patients (Clerri “30 Data-Backed Insights” 2025, citing BoomCloud research).

Active dental DSO platforms in 2026

The list below covers the most active DSO and PE-backed specialty platforms in the 2024-2026 cycle. This is who will see your teaser. Practice counts are point-in-time and shift fast; sources include Becker’s Dental Review DSO profiles 2024-2026, Group Dentistry Now monthly DSO Deal Roundups, PrivSource, Medix Dental “15 Largest DSOs in the US for 2026”, Charlesbank and Warburg Pincus press releases (November 2024), Oak Hill Capital and Blue Sea Capital portfolio pages, and CT Acquisitions’ 2026 Dental DSO PE Roll-Up Tracker.

Add to that list the strategic and ancillary buyers. Henry Schein (NASDAQ: HSIC) is the dominant dental distribution and equipment company and runs Henry Schein Dental Practice Transitions as a brokerage. Henry Schein is not a US clinical roll-up acquirer of practices but is a major exit buyer for dental technology and supply businesses. Mid-market regional DSOs (NADG, 42 North Dental, Sage Dental, Dental365, Mortenson Dental Partners) actively buy doctor-owned multi-location groups inside their footprint, and many of the monthly DSO add-on transactions tracked by Becker’s Dental and Group Dentistry Now are regional-DSO-to-doctor deals. Hospital systems and academic medical centers selectively acquire oral and maxillofacial surgery practices to support trauma call and head-and-neck programs; volume is low compared to PE platform deals but the multiples can rival PE on the right strategic fit. Dentalcorp (Canada, TSX-listed) was taken private by GTCR in Q1 2026 close at C$2.2B equity / C$3.3B EV (C$11/share, 33% premium to 20-day VWAP), at roughly 11x EBITDA per industry analysis, supporting 575+ locations and 10,600+ team members (Scope Research deal note; Dentalcorp investor news release September 26, 2025; Businesswire December 4 and 9, 2025).

Dental Practice Valuation in 2026 (What You Are Actually Worth)

The dental market uses TWO valuation conventions in parallel, and you should know both. Sub-$1M-collections solo practices still trade on a percent-of-collections asset-purchase basis to local doctor-buyers and small DSO tuck-ins. Above roughly $1M to $1.5M EBITDA, the math flips to EBITDA multiples and PE and DSO platforms become the dominant exit lane. Specialty practices (orthodontics, oral surgery, endodontics, periodontics, pediatric dentistry) command structurally higher multiples than general dentistry across both conventions.

Percent of collections (the legacy convention)

Most general dental practices sell for 65% to 85% of annual collections, with most falling in the 70% to 85% range in 2025 (DentalCPAUSA “How Much Should You Pay for a Dental Practice in 2025”; Professional Transition Strategies “What Percent of Collections is a Dental Practice Worth”; Jaffe Law “2025 Valuation Guide”). By specialty:

Source: Professional Transition Strategies, citing internal cross-source synthesis (2025).

The honest caveat: percent of collections is misleading at scale because it ignores profitability. As Professional Transition Strategies puts it, “an office that collects $800K but keeps half of it is worth more than one collecting $1M but only keeps 25%.” A $1M-collections general practice selling at 70% equals a $700K headline price, vs. the same practice on an EBITDA basis at $200K adjusted EBITDA times 5x equals $1M. The EBITDA path often produces a higher number even for sub-$1M-collections practices if the practice is well-run.

EBITDA multiples (the convention that controls everything above $1M EBITDA)

Source: FOCUS Investment Banking 2026 Dental Practice EBITDA Multiples report; FOCUS Oral Surgery Practice Valuation 2025 Update; FOCUS Orthodontic Practice Valuation 2026 Report; FOCUS Pediatric Dentistry Practice Valuation 2025 Update; DentalCPAUSA 2025; CT Acquisitions 2026 Dental DSO PE Roll-Up Tracker; Sorso “Dental Practice EBITDA Multiple 2026”; UNC Carolina Digital Repository “DSO Practice Valuation Multiples Explained.”

Specialty-specific detail worth noting: oral surgery is the highest-multiple dental specialty. FOCUS Investment Banking reports OMS practices at $1M to $3M EBITDA trade at 7x to 9x, $3M to $5M at 9x to 11x, $5M+ at 11x to 13x, and premium multi-state OMS platforms at 12x to 15x+. Orthodontics platforms (5+ locations or $3M+ EBITDA) trade at 9x to 11x EBITDA / 1.4x to 1.8x revenue, and ortho + pedo hybrid groups command 9x to 12x EBITDA / 1.5x to 1.9x revenue because of cross-referral economics (FOCUS specialty reports 2025-2026). Endodontics and periodontics trade at the lower end of specialty EBITDA multiples (5x to 8x add-on, 8x to 11x platform-fit) because deal volumes are smaller and platforms are fewer; Endodontic Practice Partners (Sun Capital) and Specialized Dental Partners are the primary roll-up buyers.

Recent disclosed dental transactions (2024-2026)

Sources: Charlesbank press release Nov 2024; Warburg Pincus press release Nov 13, 2024; Businesswire Nov 13, 2024; Axios Pro Health Tech Deals Nov 13, 2024; Scope Research deal note; Dentalcorp investor news release Sept 26, 2025; Businesswire Dec 4 and Dec 9, 2025; DrBicuspid; B. Riley Securities advisory release; PE Hub on Oak Hill / USOSM; Group Dentistry Now DSO Deal Roundup Jan 2025; Tend / Oak HC/FT press release Feb 2025; Private Equity Stakeholder Project Mar 2025 monthly report on Riccobene. The signal across these deals: very few sub-$5B dental DSO transactions disclose EBITDA multiples publicly. The two clean public comps are Dentalcorp (~11x EBITDA take-private) and MB2 (high-teens sponsor-to-sponsor recap). Add-on tier comps in the prior table come from FOCUS Investment Banking, Becker’s Dental, Precision Dental Analytics, and CT Acquisitions synthesizing observed activity rather than disclosed deal-by-deal.

The 12 Value Levers That Move Your Multiple (Ranked by Impact)

These are the levers that move dental multiples in the 24 months before a sale. Each one has a current state, a target state, and an estimated financial impact. The ordering is by dollar impact per unit of effort, based on cross-source synthesis from Precision Dental Analytics, FOCUS Investment Banking, MyBCAT, Clerri, DentalHQ, BoomCloud, Cast Hub, DentalPitch, and CT Acquisitions’ own DSO underwriting playbook.

Lever 1: Build hygiene recall to 85%+ and pre-booking to 85%+

Current: Reactive recall scheduling, ~60% to 65% reappointment (national average), hygiene production sitting at 22% to 26% of total collections. Target: 85%+ recall reappointment, 85%+ pre-booking, hygiene production at 28% to 35% of total. Impact: MyBCAT cites recall rate as “the single metric that most frequently separates $500K practices from $1M practices” (MyBCAT 2025). A single practice retaining 25 to 30 additional patients per month through improved recall adds $84K to $108K of annual production. At a 6x multiple with 30% to 40% EBITDA flow-through, that single lever creates $150K to $260K of enterprise value per practice. Across a 20-practice group, a 10% recall improvement adds approximately $1.68M in annual production (Cast Hub 2026). How: Pre-block hygiene chairs 6 months out. Stored payment on file with auto-text reminder cadence. Tie front-office bonus to recall reappointment rate. Add a hygienist if the chair is hitting 85% utilization.

Lever 2: Launch or grow an in-house membership plan

Current: No membership plan, or under 5% of patient base enrolled, no recurring monthly revenue line on the P&L. Target: 10%+ of active patient base on a $35 to $49/month plan (the pricing sweet spot per DentalHQ March 2025), automatic credit card billing, 50% to 60% profit margin after costs. Impact: Membership patients spend 2x to 4x more annually than non-member uninsured patients and complete 5.9 procedures per year vs. 2.4 for uninsured patients (Clerri 2025, citing BoomCloud research). Patient retention jumps from approximately 50% to 90%. Membership patients generate $1,276 annually vs. $469 from uninsured (Clerri). The recurring revenue line directly defends multiple expansion. Estimated +0.5x to 1.0x EBITDA multiple uplift for a meaningful membership program (estimate based on cross-source synthesis with FOCUS and CT Acquisitions valuation drivers). How: DentalHQ, BoomCloud, Plan for Health, Quality Dental Plan, and Kleer are the most-cited platforms. Train front office on a conversion script. Hygienist and front-desk incentive on enrollment.

Lever 3: Shift payer mix toward FFS, cash, and membership; away from Medicaid and low-margin PPO

Current: 70%+ PPO, 20%+ Medicaid, under 10% FFS / cash. Target: Under 25% government payer (Medicaid + state programs), balanced PPO with negotiated above-UCR fee schedules where possible, growing FFS or membership-plan share. Impact: Government payer above 35% suppresses the multiple by 10% to 30% and restricts the buyer pool (Precision Dental Analytics “11 Underwriting Criteria”). FFS-heavy practices command premium pricing. Estimated 0.5x to 1.5x EBITDA multiple uplift from moving 35%+ government to under 25%. How: PPO fee renegotiation cycle initiated 12 to 18 months pre-sale (PPO Negotiation Solutions, US Dental Analytics, and PPO Experts are the named negotiators). Strategic drop of lowest-paying PPO plans. Membership plan growth (Lever 2) as the new patient-attraction tool.

Lever 4: Move owner-doc production below 35%

Current: Owner doc produces 50%+ of collections; the owner is the practice. Target: Owner produces under 35% of collections; two or three associates carry the balance. Owner remains clinically active but is not the production engine. Impact: “Founder >40% production triggers post-close revenue deterioration modeling and discount” (Precision Dental Analytics). At above 50% owner production, the multiple haircut estimate is 1.0x to 2.0x EBITDA. On a $1.5M EBITDA practice that is $1.5M to $3M of price. Owner-doc concentration is the single most-cited multiple haircut across dental sell-side advisory content. How: Associate hire 18 to 24 months pre-sale. Build an associate-doc patient transition plan (assign hygiene-driven new patients to associates first; the owner sees emergencies and complex cases only). Document SOPs so the practice runs without the owner’s direct involvement on day-to-day operational decisions.

Lever 5: Specialty mix expansion (implants, ortho / aligners, in-house endo, in-house perio)

Current: General-only practice that refers out implants, endo, perio, and complex restorative. Target: In-house specialty service offerings that lift average ticket and shift the practice classification toward “specialty-leaning general” or “multi-specialty.” Impact: Specialty practices trade at 2x to 4x higher EBITDA multiples vs. general (CT Acquisitions 2026; FOCUS specialty reports). On a $1.5M EBITDA practice, doubling the implant case count from 50 to 100 cases per year at $3K to $6K per case (Fortune Business Insights / Grand View Dental Implants Market 2025) adds approximately $200K to $300K in collections at high gross margins, lifting EBITDA materially. The category shift from “general-only” to “multi-specialty” can move the practice up a full valuation band (e.g., add-on at 7x to emerging platform at 9x). How: Owner CE in implants, IV / oral sedation, Invisalign certification. Hire or partner with a part-time specialist (perio / endo) to do in-house referrals. Add CBCT and iTero or Trios to support the workflow.

Lever 6: Adopt and clean a modern PMS plus digital workflow

Current: Old Dentrix or Eaglesoft installation with dirty data, no digital impressions, no CEREC, no CBCT. Target: Modern practice management system (Open Dental for sub-$1M to $3M practices, up-to-date Dentrix / Eaglesoft or Curve for larger), iTero or Trios for digital impressions, CBCT for implant planning, CEREC if in-house lab work is planned. Clean data hygiene at the chart level. Impact: Direct EBITDA lift via efficiency (iTero direct integration with Dentrix / Eaglesoft eliminates manual data entry per Mentera and ai.dentist). Estimated +0.5x to 1.0x multiple uplift on the speed and credibility of diligence data-room responses and on post-close platform integration. Open Dental migration saves 40% to 60% on annual software costs vs. Dentrix (ai.dentist). How: 24-month run-up. Budget $30K to $80K for the full digital workflow upgrade (CBCT alone is $60K to $150K; iTero subscription is $400 to $700/month). PMS migration over 6 to 12 months with data cleanup.

Lever 7: De-concentrate revenue from any single payer or referral source

Current: One PPO contract drives more than 25% of revenue; one referral specialist drives 30%+ of new patients; or one large employer-group fee schedule is the main growth driver. Target: No single payer above 15%; multiple new-patient sources; meaningful direct-to-consumer marketing. Impact: Concentration triggers the same buyer discount as it does in any industry. Loss of Delta PPO Premier on a sale alone reduces collections on Delta patients by 25% to 40% (PPO Negotiation Solutions). If 40% of revenue is Delta and 25% of that revenue evaporates on transition, that is a 10% top-line hit, multiplied at sale. How: Diversify lead sources (Google Ads, Google Local Service Ads, SEO, social, referral programs). Renegotiate underperforming PPO fee schedules 12 to 18 months pre-sale.

Lever 8: Clean EBITDA add-back hygiene

Current: Owner personal expenses mixed through the business; related-party rent at above-FMV with no appraisal; no add-back schedule. Target: Every add-back documented as it happens with the underlying invoice or payroll record; related-party rent appraised at FMV; clean family-payroll documentation. Impact: Every defensible adjusted-EBITDA dollar gets multiplied at sale. At a 7x multiple, $100K of clean add-backs equals $700K of additional sale price (Morgan & Westfield QoE guide). DentalPitch reports its QoE-supported add-back work “contributes to 20% to 40% higher final outcomes” (DentalPitch). How: Adopt a monthly add-back log starting today. Document the business purpose of every charge. Get an FMV rent appraisal if the owner owns the real estate.

Lever 9: Working capital normalization (with dental-specific deferred revenue isolation)

Current: Wildly seasonal A/R from the Q4 deductible spike; prepaid Invisalign and aligner cases not isolated on the balance sheet; membership-plan prepaid months commingled with operating revenue. Target: TTM-average working capital is stable and predictable; deferred revenue on prepaid aligner cases shown as a separate liability; membership-plan deferred revenue shown as a separate liability. Impact: The working capital peg is set off the TTM average (per BDO and Morgan & Westfield). Volatile working capital lets the buyer set a higher peg, which subtracts from purchase price. Bass, Berry & Sims notes prepaid services “create deferred revenue liabilities affecting valuation and working capital adjustments” and “buyers should account for these obligations through escrows or purchase price deductions” (Bass Berry “Key Considerations for DSO Transactions”). Estimated poorly managed working capital plus deferred revenue costs 2% to 5% of enterprise value at close. How: A/R cleanup, escheatment compliance on aged credit balances (Precision Dental Analytics example: $84K of aged credits equals $113K liability after state penalties), separate GL accounts for prepaid Invisalign cases and for membership plans.

Lever 10: Real estate decision (own or lease, and the sale-leaseback option)

Current: Owner owns the building and leases to the operating practice at above-FMV related-party rent, all inside the same entity or in an LLC at a related-party rent that has never been benchmarked. Target: Real estate in a separate LLC at FMV NNN lease to the operating company, with a clear path for the buyer to either assume the lease or buy the real estate. Impact: Separating real estate avoids forcing the buyer to underwrite property exposure. DSO platform buyers usually do not want to own real estate. A sale-leaseback to a medical-real-estate REIT (Healthcare Trust of America, Physicians Realty, Anchor Health Properties, MedCore) can convert up to 100% of property market value into cash, vs. 70% to 80% LTV via traditional financing. Estimated +0.5x to 1.0x multiple uplift on the operating company. How: Get an FMV market rent study now. Restruck rent to FMV. Decide pre-marketing whether the real estate is in or out of the deal.

Lever 11: Compliance scrub (the dental-specific kill-list)

Current: License binders sit in the front office; OIG screening has never been run; no DEA assignability plan; OSHA program is informal; D2950 utilization has never been benchmarked. Target: Every provider screened against the HHS-OIG LEIE monthly with a documented log; DEA registration current per provider; state dental license, radiograph license, and sedation permit current per provider; OSHA bloodborne pathogen program documented; OSHA log up to date; HIPAA risk assessment refreshed annually; CDT code utilization benchmarked vs. Cotiviti national norms (Precision Dental Analytics underwriting criterion #3). Impact: Each of these can kill or re-trade the deal. CDT upcoding alone has been called the #1 EBITDA evaporation factor at confirmatory. See the deal-killer section below for the specific D2950 math. How: Cover this in months 24 to 12 of the run-up, before the sell-side QoE. Use ExclusionScreening.com, ProviderTrust, Verisys, or Ntracts for monthly OIG / SAM screening. Engage outside healthcare counsel to audit Stark Law and Anti-Kickback exposure on any related-party arrangement (especially supply purchasing from owner-controlled entities, lab fee splits, marketing tied to a referral source).

Lever 12: Restructure associate compensation and non-competes in advance

Current: Associates on handshake or weakly-drafted agreements with no enforceable non-compete; or non-compete radius and duration too broad to enforce. Target: Every associate on a written employment agreement with a state-appropriate restrictive covenant (typically 6 to 12 months, narrow geographic radius tied to the actual patient base) and a non-solicit. Restrictive covenants drafted to survive scrutiny in the operating state. Impact: The buyer-side concern is post-close associate flight to nearby competition or to opening a competing practice. Weak associate restrictive covenants are a known dental deal-killer (Bass Berry; DDSLawyers; Chelle Law). State variance is huge: California refuses to enforce most non-competes under B&P 16600 (with a carved-out exception for sale of business at 25%+ ownership). Florida and Georgia enforce reasonable radius restrictions. Massachusetts, Illinois, Washington, and New York tightened recently. Texas SB 1318 (effective 2025) added new constraints on dentist non-competes (Texas Dental Association). The federal FTC non-compete ban was vacated September 5, 2025 (federal district court ruling, as covered by DDSLawyers and Group Dentistry Now), so state law continues to control. How: Engage dental-specialized employment counsel 18 to 24 months pre-sale. Re-paper associate agreements with state-appropriate restrictive covenants and adequate consideration.

What PE and DSO Buyers Ask Before They Send an LOI (The Pre-LOI Diligence Stack)

Before a DSO or PE-backed dental platform commits to a letter of intent, they ask for a focused diligence package. The list below is the real ask from active 2026 dental DSO buyers in CT Acquisitions’ pipeline, with the “why” and “how to prepare” sourced from Bass, Berry & Sims, Mandelbaum Barrett, DDSLawyers, Rivkin Radler, Practice Orbit, Cranfill Sumner, FOCUS Investment Banking, and Professional Transition Strategies.

1. Income statements for 2024, 2025, and the latest trailing twelve months

Why PE asks: They are building the LTM EBITDA they will multiply. They want to see trend (growth rate, margin trajectory), seasonality (dental is less seasonal than HVAC but year-end deductible-driven Q4 spikes are real), and any one-time movers. LTM bridges the most recent year-end and today, so the headline price reflects current run-rate, not stale data.

How to prepare: Accrual-basis P&L by month, mapped to a clean chart of accounts. Service-line P&L broken out by hygiene, restorative, implants, ortho (if offered), perio, endo, OMS, and cosmetic where possible. Reconcile to tax returns so there are no surprises in confirmatory diligence.

2. Balance sheet at the latest month

Why PE asks: Two reasons. First, to start sizing the working capital peg they will set in the purchase agreement. Second, to identify net debt and debt-like items. Dental-specific debt-like items: deferred revenue on prepaid Invisalign cases (huge), prepaid teeth-whitening packages, unused membership-plan months, equipment leases on CBCT / iTero / CEREC / chairs, unfunded compensation accruals, and capital lease balances on operatories.

How to prepare: Tie the balance sheet to the trial balance. Isolate deferred revenue on prepaid aligner cases as a separate line. Bass, Berry & Sims notes prepaid services “create deferred revenue obligations that must be addressed in the transaction” and these “fall on the buyer post-closing” (Bass Berry “Key Considerations for DSO Transactions”).

3. Add-back estimates and the adjusted EBITDA bridge

Why PE asks: They want a preview of the adjusted EBITDA story before they sink diligence cost into the file. Aggressive or undocumented add-backs erode trust in the broader number.

How to prepare: Build the bridge from book EBITDA to adjusted EBITDA, line by line. Document every add-back with the underlying invoice or payroll record. Common dental add-backs that hold up: owner clinical compensation above market (if the owner-doc produces $1M and a replacement associate would cost approximately 30% to 35% of production / $300K to $350K, the delta adds back); owner family members on payroll for unclear duties; owner vehicle, personal travel, country club; owner CE that is more personal than business; related-party rent above FMV (added back to the FMV delta with an appraisal on file); one-time tech rollouts (CEREC implementation, iTero rollout, PMS migration); COVID-era ERC and PPP forgiveness mishandled in books; one-time legal fees from a divorce or unrelated litigation. Sources: Morgan & Westfield QoE guide; DentalPitch; Brentwood Growth.

4. Anonymized provider and employee roster (titles, start dates, pay structure, classification)

Why PE asks: Three things. (a) Provider depth and tenure. Are associates W-2 or 1099? Are they on production-based comp at 30% to 35% (industry norm)? Will they stay post-close? (b) Owner-dependence test: who produces what share of collections? Any provider doing 35%+ of collections, especially the owner, is a key-person risk that hits the multiple. (c) Hygienist headcount vs. chair capacity vs. recall demand.

How to prepare: Roster columns: role (DDS, RDH, DA, front office, biller), license number, hire date, full-time vs. part-time, W-2 vs. 1099 (with classification rationale), compensation structure (base + production %, hourly, salary), and any active non-compete or non-solicit. Calculate provider-by-provider production. Flag any provider doing 35%+ of collections.

5. Revenue breakdown by service line (with procedure counts and average fee per CDT code)

Why PE asks: This is the single most diagnostic exhibit. It tells them recurring revenue density (hygiene 28% to 35% target per Precision Dental Analytics), specialty mix lift (any in-house specialty work commands premium), implant volume trend, and average fee discipline by CDT code.

How to prepare: Pull it straight from Dentrix, Eaglesoft, Open Dental, Curve, or whatever PMS is in place. Show total production and collections by service line for 3 years plus LTM, procedure counts by major CDT code, average fee per code, hygiene production as % of total (target 28% to 35%), specialty production as % of total, and implant case count and revenue at $3K to $6K per case (Fortune Business Insights / Grand View Dental Implants Market 2025).

6. Patient and membership plan data (active patients, new-patient count, recall rate, membership enrollment)

Why PE asks: The active patient base is the asset they are buying. Recurring revenue from hygiene recall and from in-house membership plans is the multiple driver.

How to prepare: Active patient count (patients seen in last 18 months) by month for the last 36 months. New-patient count by month with source attribution where possible. Hygiene recall rate calculated as the % of due-for-recall patients who reappointed within the target window (target 85%+ per MyBCAT; Cast Hub; Precision Dental Analytics; national average 65% to 74%). Hygiene pre-booking rate (target 85%+). Membership plan enrolled member count, monthly fee, plan mix, ARR snapshot, churn. PPO contract roster with effective dates, fee schedules, and assignment language. Medicaid enrollment status by state and per provider.

7. Five-year operating plan

Why PE asks: PE underwrites a forward case (years 1 through 5 post-close). They overlay their own model but want to see whether you understand your own levers.

How to prepare: A simple operating model: revenue by service line, gross margin assumptions, overhead growth, EBITDA. Include capacity build (chairs added, hygienists added, associate hires), planned specialty additions, pricing actions, and any expansion territories or new locations on deck.

8. Equipment, CBCT, scanner, and lab list

Why PE asks: Three reasons. CapEx forecast (chairs, CBCT, iTero / Trios, CEREC mill, laser equipment depreciate; replacement cycle is roughly 7 to 10 years). Capital leases (debt-like and come out of purchase price). Tech-stack compatibility with platform standards.

How to prepare: Spreadsheet of major equipment with purchase date, financing status (owned, financed, leased, residual), monthly payment, condition. Flag any pending recalls or open service contracts.

9. PPO contract roster and Medicaid enrollment by state and provider

Why PE asks: Payer transferability is the single most common dental-specific re-trade vector. Delta PPO contract assignment is a known pain point (PPO Negotiation Solutions). Medicaid credentialing varies by state and requires per-provider re-enrollment that the new ownership entity often cannot accelerate.

How to prepare: Build a payer matrix: every PPO carrier with effective date, fee schedule, assignment clause, change-of-control language, in-network status, and contract expiration. State-by-state Medicaid enrollment status per provider with credentialing dates. Flag every contract that is provider-specific (vs. entity-level) so the buyer knows what re-credentialing burden they are inheriting.

Confirmatory Diligence (After You Sign the LOI)

Once an LOI is signed and exclusivity starts (typically 60 to 120 days for dental per DDSLawyers and Mandelbaum Barrett), the buyer runs parallel workstreams over 6 to 10 weeks (Practice Matchmaker; Mandelbaum Barrett). This is the depth of inspection your practice will undergo. If anything was hiding, it surfaces here.

1. Quality of Earnings (QoE). Outside accounting firm runs revenue cut-off testing, deferred revenue analysis on prepaid Invisalign and aligner cases (huge for dental), CDT-code utilization benchmarking, expense normalization, add-back validation, and working capital trends. Buyer QoE cost is typically $50K to $250K for a $1M to $10M EBITDA dental practice. Output is an adjusted EBITDA number the buyer locks into the model.
2. Clinical chart audit. A sample of patient charts is checked for documentation supporting billed codes. The single most-flagged code: D2950 core buildup. National benchmark says D2950 should appear on 30% to 40% of crowns; practices at 80% to 92% trigger a clinical audit and downward adjustment. Other commonly flagged codes: D9223 / D9243 sedation; D4341 / D4342 SRP without supporting periodontal documentation (Cap Line Dental Services; ADCA “Accurate Dental Coding”; Bass Berry; Anaya Dental; Teero).
3. Insurance and payer contract audit. PPO contract review for assignment language. Many PPO contracts do not transfer in an asset purchase. The new entity must re-credential with every payer (60 to 90 days per carrier on average, sometimes 7 months end to end per US Dental Analytics). Medicaid credentialing requires more extensive ownership disclosures, compliance screenings, and background checks (Dental Claim Support; American Practice Consultants). Delta is the most cited transferability problem: the buyer will often “only receive Delta PPO rates” rather than Delta Premier in many sales, reducing collections by 25% to 40% on Delta patients (PPO Negotiation Solutions).
4. Legal. Entity good standing in every operating state; dental license per provider; DEA registration per provider; OIG exclusion screening on every employed dentist (the LEIE has 82,229 entries as of 2026 per Exclusion Screening). State Stark Law and Anti-Kickback compliance review on any related-party arrangement. Litigation history. Restrictive covenant scope review per state.
5. HR and payroll. W-2 vs. 1099 classification audit on associates and hygienists, I-9 compliance, wage-and-hour exposure, PTO accrual, EEOC / DOL claim history, and non-compete enforceability in every operating state.
6. Compliance and regulatory. OIG exclusion check on every provider and key employee (mandatory monthly LEIE check; civil money penalties up to $24,947 per violation per the 2026 inflation adjustment per Exclusion Screening 2026). State dental board good-standing per provider. DEA registration current and assignable. OSHA bloodborne pathogen program, sharps log, sterilization protocols. HIPAA risk assessment in file. Mercury amalgam separator EPA compliance (federal rule effective July 14, 2020). Radiation safety and x-ray equipment inspection records.
7. Real estate and lease. Change-of-control language in every lease. Lease assignment requires landlord consent in most cases (15 to 30 day response window typical). Personal guarantees often remain unless explicitly released. Typical assignment timeline is 6 to 10 weeks (Realty Lease Consultant; Cirrus Consulting; Joe Rossi & Associates; IPG SF; Kamkari Law).
8. Tax. Federal income, payroll, and sales / use tax on any retail items if a state taxes them.

Why You Should Pay for Your Own Quality of Earnings Before Going to Market

A sell-side QoE is your own outside CPA firm’s quality-of-earnings report, paid for by you, before you go to market. It does three things: it pre-empts the buyer’s QoE by getting to the adjusted EBITDA number first with documentation; it surfaces issues you can fix before the buyer sees them; and it tightens the EBITDA number you take to market, which directly drives the headline price. For dental specifically, the seller-side QoE pre-empts three known re-trade vectors: (a) CDT upcoding on codes like D2950, (b) deferred-revenue treatment on prepaid Invisalign cases, and (c) owner-doc clinical compensation normalization (the buyer will replace the owner-doc with a market-rate associate, typically at 30% to 35% of collections, and the difference adds back).

Cost

• $25K to $40K for QoE on a dental practice with under $5M revenue and clean books (Eton Venture Services 2025; Morgan & Westfield).
• $35K to $75K typical range for sell-side QoE on a healthy multi-location group or specialty practice with $5M to $15M revenue (Kahn Litwin Renza; Eton 2025).
• Up to $150K for complex multi-entity dental groups with messy add-backs, multiple states, or sponsor-prep level rigor.

The dental-specific lift over a generic services QoE comes from: prepaid services treatment, payer mix analysis, CDT code utilization audit, provider-by-provider production analysis, hygiene recurring-revenue documentation, and membership-plan ARR substantiation.

ROI

Generic-industry QoE ROI example commonly cited: $25M revenue, $5M EBITDA business. Moving the multiple from 5x to 6x equals $5M of additional sale price. A $50K QoE investment supporting the 1x lift equals 100x ROI (Eton Venture Services “Quality of Earnings Report Cost”, 2025). Dental-specific commentary: DentalPitch reports its QoE-style process “supports add-backs and reduces uncertainty, increasing buyer confidence and often contributing to 20% to 40% higher final outcomes” (DentalPitch “How to Increase Dental Practice EBITDA Before Sale”). On a $3M EBITDA practice at 8x equals $24M baseline, a 20% lift is $4.8M of additional price.

Deal-Killers That Re-Trade Dental Transactions (Avoid These)

These are the recurring kill-shots cited across dental M&A advisory content, DSO transaction counsel publications, and confirmatory diligence playbooks. Most are fixable in 12 to 24 months. None of them are fixable in 30 days.

1. PPO contract assignment problems (Delta Premier the worst offender)

Many PPO contracts are provider-specific and not assignable to a new owner-entity. In Delta specifically, the new buyer-entity will typically “only receive Delta PPO rates” rather than Delta Premier rates, which reduces collections on Delta patients by 25% to 40% (PPO Negotiation Solutions “How to Prepare PPO Contracts for a Smooth Dental Practice Transition”). The transition period during which the buyer operates out of network can stretch 4 weeks to 7 months end to end (US Dental Analytics). PPO contract risk that is unclear or out of date “always reduces the sale price” (US Dental Analytics). Run the credentialing process as soon as the asset purchase agreement is signed; some carriers allow pre-credentialing contingent on closing.

2. Medicaid concentration above 25% to 35%

Government payer above 35% of collections suppresses the multiple by 10% to 30% and restricts the buyer pool (Precision Dental Analytics). Medicaid credentialing requires extensive ownership disclosures and additional compliance checks beyond commercial credentialing (Dental Claim Support “Medicaid Credentialing for Dentists”; American Practice Consultants). State Medicaid programs sometimes require a per-provider re-enrollment that the new ownership entity cannot accelerate.

3. Owner-doc producing 50%+ of collections (key-person risk)

Founder above 40% production triggers post-close revenue deterioration modeling and a discount; above 50% can move the multiple down 1.0x to 2.0x or trigger a structure renegotiation (heavy earnout, multi-year post-close employment commitment, larger holdback) (Precision Dental Analytics; Bass Berry; Mandelbaum Barrett).

4. CDT code upcoding (D2950 the most flagged)

D2950 core buildup billed on too high a percentage of crowns is the most-flagged CDT pattern in confirmatory diligence. National benchmark says D2950 should be on 30% to 40% of crowns; practices at 80% to 92% trigger a clinical audit. Precision Dental Analytics gives the math: $108K of non-compliant D2950 revenue removed at a 9x multiple equals $972K erased from enterprise value. A 2024 OIG report has been cited across dental coding compliance publications referencing a $250K fine for systematic D2950 upcoding (Cap Line Dental Services; ADCA “Accurate Dental Coding”; Bass Berry; Anaya Dental; Teero CDT Code reference). The $250K figure is treated here as cited industry consensus rather than a primary OIG settlement document (estimate). Other commonly flagged codes: D9223 / D9243 sedation; D4341 / D4342 SRP without supporting periodontal documentation.

5. Weak or unenforceable associate restrictive covenants

State variance is huge. California refuses to enforce most non-competes under Business and Professions Code 16600 (with a carved exception for sale of business at 25%+ ownership) (DDSLawyers; Chelle Law “Are Dental Associate Non-Competes Enforceable”). Other states have tightened recently (Massachusetts, Illinois, Washington, New York). Texas SB 1318 (2025) added constraints on dentist non-competes (Texas Dental Association). The federal FTC non-compete ban was vacated on September 5, 2025 (federal district court ruling, covered by DDSLawyers and Group Dentistry Now), so state law continues to control the question. Buyers price post-close associate-flight risk into the deal when restrictive covenants are weak or unenforceable in the operating state.

6. OIG / LEIE exclusion on any provider or key employee

Every provider must be screened against the HHS-OIG List of Excluded Individuals / Entities (82,229 entries as of 2026, updated monthly per Exclusion Screening “Definitive Guide to OIG Exclusions”). Civil money penalties run up to $24,947 per violation per the 2026 inflation adjustment, plus False Claims Act exposure. Any flagged provider is a closing blocker.

7. Stark Law and Anti-Kickback exposure on related-party arrangements

Common dental Stark / AKS exposure points: (a) related-party lab arrangements (owner owns the lab and the practice pays above-FMV lab fees); (b) related-party supply arrangements; (c) ownership stakes in imaging centers or surgery centers patients are referred to; (d) above-FMV office leases from owner-controlled real estate. OIG enforces Stark on a strict-liability basis (no intent required) and updated its FAQ guidance on April 23, 2026 with renewed FMV and intent focus (SovDoc “Physician’s Guide to Stark Law”; Leech Tishman “OIG Updates FAQs”; DMC Counsel; Dentistry Today “Recent Lawsuits”).

8. DEA registration and state license transferability

DEA registration is provider-specific. The new owner-entity needs every provider’s current DEA. State dental license per provider must transfer or remain in good standing post-close (state-by-state board variation). State-specific sedation permits and radiograph licenses are similarly per provider. If the owner-doc holds the only sedation permit and exits at close, the practice loses the entire sedation revenue line until a new permitted provider is in seat.

9. Lease change-of-control and personal-guarantee traps

Most dental office leases include change-of-control language treated as an assignment requiring landlord consent. Personal guarantees often remain in effect after assignment unless explicitly released, pre-negotiated, or addressed at transfer (Realty Lease Consultant; Joe Rossi & Associates; Cirrus Consulting Group; Kamkari Law “Dental Office Lease Clauses to Avoid”; IPG SF “Dental Leasing 101”; Henry Schein “Practice Sale Woes: It’s All in the Dental Office Lease”). Typical assignment timeline is 6 to 10 weeks. The landlord consent “is not to be unreasonably withheld” in well-drafted leases but is a real delay risk in poorly drafted ones. Some leases can cost 25% to 75% of sale earnings in unrecoverable lease friction (Joe Rossi & Associates).

10. Deferred revenue on prepaid Invisalign and aligner cases not isolated

Prepaid Invisalign cases are a deferred-revenue liability the buyer treats as debt-like. If not separately tracked on the balance sheet, the buyer’s confirmatory will surface it and re-trade the purchase price (Bass Berry “Key Considerations for DSO Transactions”; Rangewell “Working Capital for Dental Practices”). On a high-Invisalign practice, the prepaid liability can be six figures, all of which comes out of price at close as a debt-like deduction.

11. Hygiene capacity gap (chairs at under 70% utilization OR fully booked with patients waiting)

Both extremes are flagged. Under-utilization signals patient leakage. Over-utilization with patients waiting weeks for a cleaning signals lost revenue (the buyer models capacity addition as a CapEx need post-close). Pre-booking below 70% and recall reappointment below 70% both trigger documentation pattern concerns (Precision Dental Analytics #7).

12. OSHA, HIPAA, and amalgam-separator non-compliance plus aged credit balances not escheated

OSHA bloodborne pathogen program gaps, sharps log gaps, sterilization documentation, HIPAA risk assessment age, and EPA amalgam separator non-compliance (federal rule effective July 14, 2020) each create closing-condition friction and small but consistent purchase-price haircuts. Aged credit balances subject to state escheatment law are a separate liability that often surfaces in confirmatory; Precision Dental Analytics gives a clean example of $84K of credits becoming a $113K liability after state penalties.

The 36-Month Dental Exit Prep Timeline

T-36 months: Cleanup phase

• Switch to accrual basis if still on cash basis
• Pick a PMS for the long run (Open Dental, Curve, or current-gen Dentrix / Eaglesoft) and clean the data
• Start tagging every potential EBITDA add-back as it happens
• W-2 vs. 1099 audit on associates and hygienists; reclassify if needed (settle exposure now while it is small)
• Restruck related-party rent to FMV with appraisal on file
• Build the org chart; identify the GM, office manager, or operations director hire or promotion
• Begin OIG monthly screening on every provider
• Stark and Anti-Kickback audit on every related-party arrangement (lab, supply, real estate, marketing)
• Begin CDT code utilization benchmarking vs. Cotiviti national norms (D2950 is the priority code)
• Begin recall reappointment and pre-booking discipline (target 85%+ by T-12)
• Launch or grow in-house membership plan if not already running
• PPO fee renegotiation cycle initiated (typically 12 to 24 months)

T-24 months: Financial discipline and KPI infrastructure

• Monthly close in 15 days; service-line P&L every month (hygiene, restorative, implants, ortho, perio, endo, OMS)
• KPI dashboard: hygiene recall rate, pre-booking rate, new-patient count, NP source attribution, average production per provider per day, hygiene production %, supply %, lab %, treatment acceptance rate, membership-plan enrollment
• Associate hires onboarded; owner production glide-path toward under 35%
• Pricing review: review and adjust UCR fees annually
• Diversification of payer mix if any single payer is above 25%
• Document SOPs for every operational role
• Build the add-back bridge as a living document
• Begin associate restrictive covenant re-paper with dental-specialized employment counsel
• Digital workflow upgrades (CBCT, iTero or Trios) live and integrated with PMS

T-12 months: QoE-ready close discipline, eliminate owner dependence

• Owner production now under 35% of collections; associates carrying the practice
• Owner takes a 2-week unplugged vacation as the stress test
• Run the sell-side QoE (budget $35K to $75K typical; up to $150K for complex multi-entity)
• Tighten balance sheet: clean A/R, escheat aged credits, isolate deferred revenue on prepaid Invisalign and membership
• Final org-chart review; backfill any gaps
• Final compliance scrub (OIG, DEA, state licenses, OSHA, HIPAA, amalgam separator, Stark and AKS)
• Lock in 12 months of clean service-line P&L for the CIM
• Lease review: confirm change-of-control language, personal guarantee status, assignment process
• Membership plan ARR snapshot ready for the CIM

T-6 months: Pre-marketing prep

• Engage M&A advisor or sell-side investment bank. For dental, name-brand sell-side advisors include FOCUS Investment Banking (dental-specialized), TUSK Practice Sales (~90% dental), Large Practice Sales (LPS), Professional Transition Strategies (PTS), McLerran & Associates / Dental Transitions, Brentwood Growth, Practice Orbit, US Dental Transitions, DDSmatch, Henry Schein Dental Practice Transitions, and Integrity Practice Sales. Brokers in the small-deal tier (sub-$1M EBITDA) charge 5% to 12% of sale price; investment banks for larger deals charge $25K to $75K monthly retainer credited against a success fee of 4% to 8% of enterprise value with Lehman or modified Lehman scaling (cross-source synthesis: TUSK; FOCUS; CTC Associates; DDSMatch South)
• CIM drafted from the QoE and operating model
• Teaser drafted (anonymized 1-pager)
• Buyer list finalized. The platform list above gives 25+ active DSO platforms as a starting set; the advisor will short-list 8 to 20 based on geographic fit, size fit, specialty fit, and current capital availability
• Virtual data room populated with everything from the pre-LOI and confirmatory sections above
• Management presentation deck built and rehearsed

T-3 months: Go to market

• Teaser distributed; NDAs collected; CIMs distributed
• IOIs collected approximately 2 to 3 weeks after the CIM goes out
• Narrow to 4 to 6 finalists for management meetings
• Management meetings; LOIs solicited
• Select LOI; sign with exclusivity (typically 60 to 120 days for dental per DDSLawyers and Mandelbaum Barrett)
• Enter confirmatory diligence (chart audit, payer audit, legal, HR, real estate, tax, 6 to 10 weeks per Mandelbaum Barrett and Practice Matchmaker)
• Definitive purchase agreement plus MSO / PC joinder structuring
• Lease assignment and PPO re-credentialing run in parallel
• Close

End to end from engagement to close: 6 to 9 months in a well-run process (Mandelbaum Barrett “Four-Phase DSO Transaction Process”; DentalReviewed 2026; TUSK Practice Sales 2026 outlook).

Frequently Asked Questions

How long should I plan for before selling my dental practice to a DSO or PE-backed buyer?

The owners who get top-quartile pricing start preparing 24 to 36 months before going to market. The minimum useful prep window is 12 months because the high-leverage levers (lifting hygiene recall from 60% to 85%+, moving owner production from 50%+ to under 35% by ramping associates, launching or scaling a membership plan, renegotiating PPO fee schedules, fixing CDT code utilization patterns like D2950, and running a sell-side QoE) need 12+ months of clean trailing-twelve-months data to be credible to a buyer. Owners who accept an unsolicited DSO offer without running a competitive process typically leave 20% to 40% on the table (TUSK Practice Sales / PR Newswire).

What is a realistic EBITDA multiple for a $1.5M EBITDA general dental practice in 2026?

For a general dental practice at $1.5M EBITDA in 2026, the range is 6x to 9x (the add-on tier per FOCUS Investment Banking 2026). The bottom of that range applies to practices with high Medicaid concentration, owner-doc producing 50%+ of collections, hygiene recall under 70%, and no in-house specialty work. The top applies to practices with under 25% government payer, owner producing under 35%, hygiene recall above 85%, a meaningful membership plan, and in-house implant or ortho work. For a specialty practice at the same $1.5M EBITDA, the range shifts to 7x to 10x. Oral surgery commands the highest specialty multiples; orthodontics and pediatric dentistry hybrid groups command structural premiums for cross-referral economics. The 36-month prep playbook moves you from the bottom of the band to the top.

Should I get a quality of earnings report done before going to market?

For dental practices at $1M+ EBITDA, yes. A sell-side QoE costs $25K to $75K typical, up to $150K for complex multi-entity dental groups (Eton Venture Services 2025). The ROI is leverage. If your QoE supports a 1x multiple uplift on a $3M EBITDA practice at an 8x baseline, that is $3M of additional sale price for a $50K to $75K investment. More importantly, a pre-market QoE surfaces the three known dental re-trade vectors (CDT code utilization on D2950, deferred revenue on prepaid Invisalign, owner-doc clinical compensation normalization) while you can still fix them, rather than during exclusivity when the buyer re-trades the deal. DentalPitch reports its QoE-supported add-back work “contributes to 20% to 40% higher final outcomes” (DentalPitch).

Will the buyer keep my associate dentists and hygienists after they buy my practice?

Almost always, yes. DSO buyers acquire practices for the patient base, the production, and the team that produces it. Associate dentists are typically offered new employment agreements with the DSO at close, often with revised compensation (production-based comp at 30% to 35% of collections is the dental industry norm). Hygienists, dental assistants, and front-office staff are typically offered continued employment on existing terms with the DSO’s benefits package layered in. The retention risk is post-close associate flight to nearby competition, which is why every associate restrictive covenant matters (see Lever 12 and Deal-Killer 5). If your state does not enforce associate non-competes (California is the headline example under B&P 16600), buyers will price that risk into the deal or use longer earnout structures and team-retention bonuses to anchor the associate base post-close.

Do I need to step back from clinical production before I sell, or just from the business side?

Both, but in different proportions. The single most-cited multiple haircut in dental valuation literature is owner-doc clinical production share above 50% of collections. The target is for the owner to produce under 35% of collections by the time the CIM goes out, with associates carrying the rest. The owner stays clinically active (you are still the practice’s identity for patients and the team), but the business is no longer dependent on you in the chair. On the business side, an office manager or operations director who already runs the day-to-day is what buyers want to see. The buyer is underwriting a practice that will retain its production and operate cleanly after you sell your equity and either step out fully or stay on as a clinical associate post-close for a 1 to 3 year transition.

What is the difference between an affiliation deal at 100% cash, a JV or sub-DSO deal with rollover equity, and a direct PE investment?

Three structures dominate dental DSO deals (Professional Transition Strategies “The 5 DSO Deal Structures Every Dental Practice Must Know”; McLerran & Associates / Dental Transitions “Unpacking DSO Deal Structures”; Dental Economics; Bass Berry). Affiliation deal at 100% cash: seller sells all equity to the DSO at close, takes the full payout, and either retires or stays on as a clinical associate for a transition period. Highest tax bill (full capital gains in year of sale). Lowest post-close optionality. JV or sub-DSO with rollover equity: seller rolls a portion of equity (typically 20% to 40%) into the DSO platform or into a sub-DSO and takes the rest in cash at close. The rolled equity participates in the platform’s next recap event (typically 3 to 7 years out). Many dentists who have rolled have seen the rolled equity double or triple at the next recap, producing a “second bite of the apple.” Lower current-year tax. Higher long-term upside if the platform executes. Direct PE investment: for the largest practices ($5M+ EBITDA, multi-location), a PE sponsor invests directly without a DSO intermediary; the seller may retain 40% to 50% and continue as CEO of the platform with a multi-year build-out plan. The right structure depends on your age, tax position, financial goals, and appetite for continued operational involvement.

What to Do Next

The dental owners who get the top-quartile multiple in 2026 all do the same three things. They start preparing 24 to 36 months before they want to be out. They build hygiene recall, membership plan ARR, and payer mix discipline so the practice presents as a defensible recurring-revenue asset, not a doctor-dependent collection of one-off procedures. And they invest in a sell-side QoE before any DSO buyer sees a CIM, so the adjusted EBITDA number that anchors the price is theirs to defend rather than the buyer’s to dismantle.

The owners who do not do this work tend to be the same owners who accept the first unsolicited DSO offer that lands in their inbox, see no competitive process, fail to address D2950 utilization or owner-production concentration in advance, and end up either re-trading 10% to 25% of price during confirmatory diligence or walking from the deal. TUSK Practice Sales has been on the record naming this pattern (TUSK Practice Sales / PR Newswire), and FOCUS Investment Banking, Bass Berry, and Mandelbaum Barrett have written similar pieces in 2025 and 2026.

If you are 12+ months from a potential exit and want a structured pre-sale optimization roadmap, CT Acquisitions has dental operations specialists in our partner network who run multi-quarter prep engagements. If you are 6 to 12 months out and ready to start the sell-side process, our M&A advisory team runs the DSO and PE buyer outreach. Buyers pay our fee, not you. Either way, the first 30 minutes are free.